2.260CAD-3.00%Mkt Cap: 5.77M CADP/E: —Last update: 2026-06-01
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kin…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap5.77M CAD
Enterprise Value37.88M CAD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-25.47M CAD
Revenue/Share—
Last Price2.260 CAD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees14
CountryCA
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.76
PEG—
EV/EBITDA-1.43
EV/Revenue—
P/S—
P/B-0.12
EPS (TTM)-14.41
EPS (Forward)-3.05
52W Range
1.02079% of range2.590
52W High2.590 CAD
52W Low1.020 CAD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE93.75%
ROA-254.37%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-21.99M CAD
CapEx (TTM)—
FCF Margin—
FCF Yield-249.01%
Net Debt31.93M CAD
Net Debt/EBITDA-1.21
Balance Sheet
Debt/Equity-1.03
Current Ratio0.55
Quick Ratio0.09
Book Value/Sh-18.7880 CAD
Cash/Share0.4000 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateJun 6, 2023
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.55M
Float1.86M
Insiders27.37%
Institutions3.91%
Short Interest
Short Ratio0.4d
Short % Float0.05%
Short % Out.0.04%
Shares Short946
Short (prev mo.)10.75K
Technical
SMA 502.304 (-1.9%)
SMA 2002.071 (+9.1%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)2.83K
Avg Vol (10d)2.12K
Technical Indicators
RSI (14)53.2
MACD0.0061
MACD Signal0.0050
MACD Hist.+0.0011
BB Upper2.521 CAD
BB Middle2.274 CAD
BB Lower2.027 CAD
BB Width21.73%
ATR (14)0.0464 CAD
Vol Ratio (20d)0.89x